Identification

Name
Pravastatin
Accession Number
DB00175  (APRD00328)
Type
Small Molecule
Groups
Approved
Description

Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6’-hydroxyl group that does not require in vivo activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.

Structure
Thumb
Synonyms
  • (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
  • Pravastatin acid
  • Pravastatina
  • Pravastatine
  • Pravastatinum
Product Ingredients
IngredientUNIICASInChI Key
Pravastatin sodium3M8608UQ6181131-70-6VWBQYTRBTXKKOG-IYNICTALSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act PravastatinTablet10 mgOralActavis Pharma Company2003-12-09Not applicableCanada
Act PravastatinTablet40 mgOralActavis Pharma Company2003-12-09Not applicableCanada
Act PravastatinTablet20 mgOralActavis Pharma Company2003-12-09Not applicableCanada
Bio PravastatinTablet10 mgOralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio PravastatinTablet40 mgOralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio PravastatinTablet20 mgOralBioenhance Medicines Inc.2001-07-122003-02-27Canada
M-pravastatinTablet10 mgOralMantra Pharma IncNot applicableNot applicableCanada
M-pravastatinTablet40 mgOralMantra Pharma IncNot applicableNot applicableCanada
M-pravastatinTablet20 mgOralMantra Pharma IncNot applicableNot applicableCanada
PravacholTablet40 mg/1OralE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-pravastatinTablet20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pravastatinTablet10 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-pravastatinTablet40 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Apo-pravastatinTablet20 mgOralApotex Corporation2001-02-27Not applicableCanada
Apo-pravastatinTablet10 mgOralApotex Corporation2001-02-27Not applicableCanada
Apo-pravastatinTablet40 mgOralApotex Corporation2001-02-27Not applicableCanada
Auro-pravastatinTablet20 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-pravastatinTablet10 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-pravastatinTablet40 mgOralAuro Pharma IncNot applicableNot applicableCanada
Ava-pravastatinTablet40 mgOralAvanstra Inc2011-10-112011-12-12Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Pal-pravastatin-asaPravastatin sodium (10 mg) + Acetylsalicylic acid (81 mg)Kit; Tablet; Tablet, delayed releaseOralPaladin Labs Inc2006-01-132015-07-31Canada
Pal-pravastatin-asaPravastatin sodium (40 mg) + Acetylsalicylic acid (81 mg)Kit; Tablet; Tablet, delayed releaseOralPaladin Labs Inc2006-01-132015-07-31Canada
Pal-pravastatin-asaPravastatin sodium (20 mg) + Acetylsalicylic acid (81 mg)Kit; Tablet; Tablet, delayed releaseOralPaladin Labs Inc2006-01-132015-07-31Canada
International/Other Brands
Elisor / Lipostat / Mevalotin / Pravaselect / Selipran
Categories
UNII
KXO2KT9N0G
CAS number
81093-37-0
Weight
Average: 424.5277
Monoisotopic: 424.246103506
Chemical Formula
C23H36O7
InChI Key
TUZYXOIXSAXUGO-PZAWKZKUSA-N
InChI
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
IUPAC Name
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
SMILES

Pharmacology

Indication

For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.

Structured Indications
Pharmacodynamics

The primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.

Mechanism of action

Pravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated in vivo. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site. Pravastatin sodium produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it effects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor-mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
Absorption

Pravastatin is rapidly absorbed with peak plasma levels of the parent compound achieved 1 to 1.5 hours after administration. The average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. These values however, are variable. Food decreases the systemic bioavailability but the lipid-lowering effect is not impacted. When 20 mg of pravastatin is given orally, the pharmacokinetic parameters are as follows: Cmax = 23.3-26.3 ng/mL; AUC = 54.7 to 62.2 ng•hr/mL.

Volume of distribution
Not Available
Protein binding

50% bound to human plasma proteins.

Metabolism

Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4. Furthermore, the major degradation product is the 3α-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound.

Route of elimination

Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration, 47% of total body clearance was via renal excretion, while 53% was eliminated by non-renal routes.

Half life

77 hours

Clearance
Not Available
Toxicity

Side effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD50= 12,000 mg/kg (orally in rat)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Pravastatin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Kinesin-like protein KIF6---(C;C) / (C;T)C AlleleEffect Directly StudiedPatients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose pravastatin.Details
3-hydroxy-3-methylglutaryl-coenzyme A reductase---(A;T)T AlleleEffect Directly StudiedPatients with this genotype have a lesser reduction in LDL cholesterol with pravastatin.Details

Interactions

Drug Interactions
DrugInteractionDrug group
6-Deoxyerythronolide BThe risk or severity of rhabdomyolysis can be increased when 6-Deoxyerythronolide B is combined with Pravastatin.Experimental
AbirateroneThe metabolism of Pravastatin can be decreased when combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Pravastatin can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe serum concentration of Pravastatin can be increased when it is combined with Acetazolamide.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Pravastatin.Approved, Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Pravastatin.Approved
AldesleukinThe serum concentration of Pravastatin can be increased when it is combined with Aldesleukin.Approved
AlmasilateThe serum concentration of Pravastatin can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Pravastatin can be decreased when it is combined with Aloglutamol.Approved
AlprazolamThe serum concentration of Pravastatin can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AluminiumThe serum concentration of Pravastatin can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Pravastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Pravastatin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
AmbroxolThe serum concentration of Pravastatin can be increased when it is combined with Ambroxol.Approved, Investigational
AmiodaroneThe serum concentration of Pravastatin can be decreased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Pravastatin can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Pravastatin.Approved, Investigational
Amphotericin BThe risk or severity of rhabdomyolysis can be increased when Amphotericin B is combined with Pravastatin.Approved, Investigational
AmprenavirThe serum concentration of Pravastatin can be increased when it is combined with Amprenavir.Approved, Investigational
AnastrozoleThe serum concentration of Pravastatin can be increased when it is combined with Anastrozole.Approved, Investigational
AntipyrineThe serum concentration of Pravastatin can be increased when it is combined with Antipyrine.Approved, Investigational
ApalutamideThe serum concentration of Pravastatin can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Pravastatin can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Pravastatin can be increased when it is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Pravastatin can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Pravastatin can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of rhabdomyolysis can be increased when Atazanavir is combined with Pravastatin.Approved, Investigational
AtomoxetineThe serum concentration of Pravastatin can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Atorvastatin.Approved
AVE9633The risk or severity of rhabdomyolysis can be increased when AVE9633 is combined with Pravastatin.Investigational
AzelastineThe serum concentration of Pravastatin can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Pravastatin can be increased when it is combined with Azithromycin.Approved
BetamethasoneThe serum concentration of Pravastatin can be increased when it is combined with Betamethasone.Approved, Vet Approved
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Pravastatin.Approved, Investigational
BicalutamideThe serum concentration of Pravastatin can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Pravastatin can be increased when it is combined with Bifonazole.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Pravastatin can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Pravastatin can be decreased when it is combined with Bismuth subnitrate.Approved, Experimental
BoceprevirThe serum concentration of Pravastatin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Pravastatin can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Pravastatin can be increased when combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Pravastatin.Approved
Brefeldin AThe risk or severity of rhabdomyolysis can be increased when Brefeldin A is combined with Pravastatin.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin.Approved, Investigational
BromocriptineThe serum concentration of Pravastatin can be increased when it is combined with Bromocriptine.Approved, Investigational
Bryostatin 1The risk or severity of rhabdomyolysis can be increased when Bryostatin 1 is combined with Pravastatin.Investigational
BuprenorphineThe serum concentration of Pravastatin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
CabergolineThe serum concentration of Pravastatin can be increased when it is combined with Cabergoline.Approved
CaffeineThe serum concentration of Pravastatin can be increased when it is combined with Caffeine.Approved
Calcium CarbonateThe serum concentration of Pravastatin can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe serum concentration of Pravastatin can be decreased when it is combined with Calcium silicate.Experimental
CandicidinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Pravastatin.Withdrawn
CapecitabineThe metabolism of Pravastatin can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe serum concentration of Pravastatin can be increased when it is combined with Capsaicin.Approved
CarbamazepineThe metabolism of Pravastatin can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe risk or severity of rhabdomyolysis can be increased when Carbomycin is combined with Pravastatin.Vet Approved
CaspofunginThe serum concentration of Pravastatin can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Pravastatin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Pravastatin can be increased when it is combined with Cerivastatin.Approved, Withdrawn
CethromycinThe risk or severity of rhabdomyolysis can be increased when Cethromycin is combined with Pravastatin.Investigational
ChloramphenicolThe serum concentration of Pravastatin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Pravastatin can be increased when it is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Pravastatin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CilostazolThe serum concentration of Pravastatin can be increased when it is combined with Cilostazol.Approved, Investigational
CimetidineThe serum concentration of Pravastatin can be increased when it is combined with Cimetidine.Approved, Investigational
Cimicifuga racemosaThe serum concentration of Pravastatin can be increased when it is combined with Cimicifuga racemosa.Approved, Experimental
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Pravastatin.Approved, Investigational
CiprofloxacinThe serum concentration of Pravastatin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Pravastatin can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Pravastatin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Pravastatin can be increased when it is combined with Clemastine.Approved, Investigational
ClindamycinThe serum concentration of Pravastatin can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe serum concentration of Pravastatin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Pravastatin can be increased when it is combined with Clomifene.Approved, Investigational
ClotiazepamThe serum concentration of Pravastatin can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe serum concentration of Pravastatin can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Pravastatin can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Pravastatin can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Pravastatin can be increased when it is combined with Cocaine.Approved, Illicit
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Pravastatin.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Coltuximab ravtansineThe risk or severity of rhabdomyolysis can be increased when Coltuximab ravtansine is combined with Pravastatin.Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Pravastatin.Approved, Investigational
Cortisone acetateThe serum concentration of Pravastatin can be increased when it is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Pravastatin can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe serum concentration of Pravastatin can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Pravastatin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Pravastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pravastatin.Approved
DabrafenibThe serum concentration of Pravastatin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Pravastatin can be increased when it is combined with Daclatasvir.Approved, Investigational
DalfopristinThe serum concentration of Pravastatin can be increased when it is combined with Dalfopristin.Approved
DanazolThe risk or severity of myopathy and rhabdomyolysis can be increased when Danazol is combined with Pravastatin.Approved
DaptomycinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Daptomycin.Approved, Investigational
DarunavirThe serum concentration of Pravastatin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Pravastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Pravastatin can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Pravastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Pravastatin can be increased when it is combined with Delavirdine.Approved
DesipramineThe serum concentration of Pravastatin can be increased when it is combined with Desipramine.Approved, Investigational
DexamethasoneThe serum concentration of Pravastatin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextropropoxypheneThe serum concentration of Pravastatin can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Pravastatin can be increased when it is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DiethylstilbestrolThe serum concentration of Pravastatin can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Pravastatin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Pravastatin.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Pravastatin.Experimental
DihydroergotamineThe serum concentration of Pravastatin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Pravastatin can be increased when it is combined with Diltiazem.Approved, Investigational
Dimethyl sulfoxideThe serum concentration of Pravastatin can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DirithromycinThe risk or severity of rhabdomyolysis can be increased when Dirithromycin is combined with Pravastatin.Approved, Investigational
DocetaxelThe serum concentration of Pravastatin can be increased when it is combined with Docetaxel.Approved, Investigational
DoramectinThe risk or severity of rhabdomyolysis can be increased when Doramectin is combined with Pravastatin.Vet Approved
DosulepinThe metabolism of Pravastatin can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Pravastatin can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Pravastatin can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Pravastatin can be increased when it is combined with Dronedarone.Approved
EconazoleThe serum concentration of Pravastatin can be increased when it is combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Pravastatin.Approved
EfavirenzThe serum concentration of Pravastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe serum concentration of Pravastatin can be increased when it is combined with Efonidipine.Approved, Investigational
ElbasvirThe serum concentration of Pravastatin can be increased when it is combined with Elbasvir.Approved
EltrombopagThe serum concentration of Pravastatin can be increased when it is combined with Eltrombopag.Approved
EnasidenibThe serum concentration of Pravastatin can be increased when it is combined with Enasidenib.Approved, Investigational
EnzalutamideThe serum concentration of Pravastatin can be decreased when it is combined with Enzalutamide.Approved
EpinephrineThe serum concentration of Pravastatin can be increased when it is combined with Epinephrine.Approved, Vet Approved
EpofolateThe risk or severity of rhabdomyolysis can be increased when Epofolate is combined with Pravastatin.Investigational
Epothilone DThe risk or severity of rhabdomyolysis can be increased when Epothilone D is combined with Pravastatin.Experimental, Investigational
EprinomectinThe risk or severity of rhabdomyolysis can be increased when Eprinomectin is combined with Pravastatin.Vet Approved
Ergoloid mesylateThe serum concentration of Pravastatin can be increased when it is combined with Ergoloid mesylate.Approved
ErgonovineThe serum concentration of Pravastatin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Pravastatin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe risk or severity of adverse effects can be increased when Erlotinib is combined with Pravastatin.Approved, Investigational
ErythromycinThe serum concentration of Pravastatin can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EthanolThe serum concentration of Pravastatin can be increased when it is combined with Ethanol.Approved
EtoposideThe serum concentration of Pravastatin can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Pravastatin can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Pravastatin can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Pravastatin.Approved
EzetimibeThe serum concentration of Pravastatin can be increased when it is combined with Ezetimibe.Approved
FelodipineThe serum concentration of Pravastatin can be increased when it is combined with Felodipine.Approved, Investigational
FenofibrateThe risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Pravastatin.Approved
FentanylThe serum concentration of Pravastatin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pravastatin.Approved
FloxuridineThe metabolism of Pravastatin can be decreased when combined with Floxuridine.Approved
FluconazoleThe risk or severity of adverse effects can be increased when Fluconazole is combined with Pravastatin.Approved, Investigational
FluorouracilThe metabolism of Pravastatin can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Pravastatin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlurithromycinThe risk or severity of rhabdomyolysis can be increased when Flurithromycin is combined with Pravastatin.Experimental
Fluticasone propionateThe serum concentration of Pravastatin can be increased when it is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Pravastatin can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Pravastatin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Pravastatin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pravastatin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Pravastatin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Pravastatin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GemfibrozilThe risk or severity of rhabdomyolysis, myoglobinuria, and elevated creatine kinase (CPK) can be increased when Gemfibrozil is combined with Pravastatin.Approved
GlyburideThe serum concentration of Pravastatin can be increased when it is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe serum concentration of Pravastatin can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GPI-1485The risk or severity of rhabdomyolysis can be increased when GPI-1485 is combined with Pravastatin.Investigational
HaloperidolThe serum concentration of Pravastatin can be increased when it is combined with Haloperidol.Approved
HistamineThe serum concentration of Pravastatin can be increased when it is combined with Histamine.Approved, Investigational
HydralazineThe serum concentration of Pravastatin can be increased when it is combined with Hydralazine.Approved
HydrocortisoneThe serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydrotalciteThe serum concentration of Pravastatin can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Pravastatin.Approved
IdelalisibThe serum concentration of Pravastatin can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Pravastatin can be increased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Pravastatin can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Pravastatin can be increased when it is combined with Imatinib.Approved
IndinavirThe serum concentration of Pravastatin can be increased when it is combined with Indinavir.Approved
IndisulamThe serum concentration of Pravastatin can be increased when it is combined with Indisulam.Investigational
IrbesartanThe serum concentration of Pravastatin can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Pravastatin can be increased when it is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe serum concentration of Pravastatin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Pravastatin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe serum concentration of Pravastatin can be increased when it is combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Pravastatin can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Pravastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pravastatin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe risk or severity of rhabdomyolysis can be increased when Ivermectin is combined with Pravastatin.Approved, Investigational, Vet Approved
IxabepiloneThe risk or severity of rhabdomyolysis can be increased when Ixabepilone is combined with Pravastatin.Approved, Investigational
JosamycinThe serum concentration of Pravastatin can be increased when it is combined with Josamycin.Approved, Investigational
KetazolamThe serum concentration of Pravastatin can be increased when it is combined with Ketazolam.Approved
KetoconazoleThe serum concentration of Pravastatin can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Pravastatin.Experimental
KOS-1584The risk or severity of rhabdomyolysis can be increased when KOS-1584 is combined with Pravastatin.Investigational
LansoprazoleThe serum concentration of Pravastatin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Pravastatin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibThe serum concentration of Pravastatin can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Pravastatin.Approved
LeflunomideThe metabolism of Pravastatin can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineThe serum concentration of Pravastatin can be increased when it is combined with Lercanidipine.Approved, Investigational
LevofloxacinThe serum concentration of Pravastatin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe serum concentration of Pravastatin can be increased when it is combined with Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Pravastatin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Pravastatin can be increased when it is combined with Linagliptin.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Pravastatin.Approved, Investigational
LobeglitazoneThe metabolism of Pravastatin can be decreased when combined with Lobeglitazone.Approved, Investigational
LomitapideThe serum concentration of Pravastatin can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe serum concentration of Pravastatin can be increased when it is combined with Lomustine.Approved, Investigational
LopinavirThe serum concentration of Pravastatin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Pravastatin can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Pravastatin can be increased when it is combined with Lorpiprazole.Approved
Lorvotuzumab mertansineThe risk or severity of rhabdomyolysis can be increased when Lorvotuzumab mertansine is combined with Pravastatin.Investigational
LosartanThe serum concentration of Pravastatin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Pravastatin can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Pravastatin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pravastatin can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe serum concentration of Pravastatin can be increased when it is combined with Lurasidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Pravastatin.Illicit, Investigational, Withdrawn
MagaldrateThe serum concentration of Pravastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium hydroxideThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe serum concentration of Pravastatin can be increased when it is combined with Manidipine.Approved, Investigational
MefloquineThe serum concentration of Pravastatin can be increased when it is combined with Mefloquine.Approved, Investigational
MepartricinThe risk or severity of rhabdomyolysis can be increased when Mepartricin is combined with Pravastatin.Experimental
MequitazineThe serum concentration of Pravastatin can be increased when it is combined with Mequitazine.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Pravastatin.Experimental
MethadoneThe serum concentration of Pravastatin can be increased when it is combined with Methadone.Approved
MethazolamideThe serum concentration of Pravastatin can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Pravastatin can be increased when it is combined with Methimazole.Approved
MethylergometrineThe serum concentration of Pravastatin can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe serum concentration of Pravastatin can be increased when it is combined with Methylprednisolone.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Pravastatin.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pravastatin.Approved, Investigational
MetronidazoleThe serum concentration of Pravastatin can be increased when it is combined with Metronidazole.Approved
MetyraponeThe serum concentration of Pravastatin can be increased when it is combined with Metyrapone.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Pravastatin.Experimental
MibefradilThe serum concentration of Pravastatin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Pravastatin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Pravastatin can be increased when it is combined with Midazolam.Approved, Illicit
MidecamycinThe risk or severity of rhabdomyolysis can be increased when Midecamycin is combined with Pravastatin.Experimental
MidostaurinThe metabolism of Pravastatin can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Pravastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MiocamycinThe risk or severity of rhabdomyolysis can be increased when Miocamycin is combined with Pravastatin.Experimental
MirtazapineThe serum concentration of Pravastatin can be increased when it is combined with Mirtazapine.Approved
Mirvetuximab SoravtansineThe risk or severity of rhabdomyolysis can be increased when Mirvetuximab Soravtansine is combined with Pravastatin.Investigational
MitemcinalThe risk or severity of rhabdomyolysis can be increased when Mitemcinal is combined with Pravastatin.Investigational
MitotaneThe serum concentration of Pravastatin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Pravastatin can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Pravastatin can be increased when it is combined with Modafinil.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Pravastatin.Approved
NatamycinThe risk or severity of rhabdomyolysis can be increased when Natamycin is combined with Pravastatin.Approved
NefazodoneThe serum concentration of Pravastatin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Pravastatin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Pravastatin can be increased when it is combined with Nevirapine.Approved
NiacinThe risk or severity of rhabdomyolysis can be increased when Niacin is combined with Pravastatin.Approved, Investigational, Nutraceutical
NicardipineThe serum concentration of Pravastatin can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Pravastatin.Approved, Investigational
NicotinamideThe serum concentration of Pravastatin can be increased when it is combined with Nicotinamide.Approved, Investigational
NifedipineThe serum concentration of Pravastatin can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Pravastatin can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Pravastatin can be increased when it is combined with Nilvadipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Pravastatin.Approved
NisoldipineThe serum concentration of Pravastatin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Pravastatin can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe serum concentration of Pravastatin can be increased when it is combined with Nitric Oxide.Approved
NorfloxacinThe serum concentration of Pravastatin can be increased when it is combined with Norfloxacin.Approved
NoscapineThe serum concentration of Pravastatin can be increased when it is combined with Noscapine.Investigational
NystatinThe risk or severity of rhabdomyolysis can be increased when Nystatin is combined with Pravastatin.Approved, Vet Approved
OlanzapineThe serum concentration of Pravastatin can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Pravastatin can be increased when it is combined with Olaparib.Approved
OleandomycinThe risk or severity of rhabdomyolysis can be increased when Oleandomycin is combined with Pravastatin.Vet Approved
OmeprazoleThe serum concentration of Pravastatin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Pravastatin can be increased when it is combined with Osimertinib.Approved
OxybutyninThe serum concentration of Pravastatin can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Pravastatin can be increased when it is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe serum concentration of Pravastatin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Pravastatin can be increased when it is combined with Palbociclib.Approved, Investigational
ParamethasoneThe serum concentration of Pravastatin can be increased when it is combined with Paramethasone.Approved
ParoxetineThe risk or severity of increased glucose can be increased when Pravastatin is combined with Paroxetine.Approved, Investigational
PatupiloneThe risk or severity of rhabdomyolysis can be increased when Patupilone is combined with Pravastatin.Experimental, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Pravastatin.Approved
PentobarbitalThe metabolism of Pravastatin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PergolideThe serum concentration of Pravastatin can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PhenelzineThe serum concentration of Pravastatin can be increased when it is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Pravastatin can be increased when combined with Phenobarbital.Approved, Investigational
PhenytoinThe serum concentration of Pravastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pravastatin can be increased when it is combined with Pilocarpine.Approved, Investigational
PimecrolimusThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Pravastatin.Approved, Investigational
PimozideThe serum concentration of Pravastatin can be increased when it is combined with Pimozide.Approved
PiperaquineThe serum concentration of Pravastatin can be increased when it is combined with Piperaquine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Pravastatin.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Pravastatin.Approved, Investigational
PosaconazoleThe serum concentration of Pravastatin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrednisoloneThe serum concentration of Pravastatin can be increased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Pravastatin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Pravastatin can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Pravastatin can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Pravastatin can be increased when it is combined with Progesterone.Approved, Vet Approved
PropofolThe serum concentration of Pravastatin can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Pravastatin.Approved
PyrimethamineThe metabolism of Pravastatin can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinidineThe serum concentration of Pravastatin can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Pravastatin can be increased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Pravastatin can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe serum concentration of Pravastatin can be increased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Pravastatin can be increased when it is combined with Raloxifene.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Pravastatin.Approved
RanitidineThe serum concentration of Pravastatin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Pravastatin.Approved, Investigational
RegorafenibThe serum concentration of Pravastatin can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Pravastatin can be increased when it is combined with Repaglinide.Approved, Investigational
ResveratrolThe serum concentration of Pravastatin can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
RidaforolimusThe risk or severity of rhabdomyolysis can be increased when Ridaforolimus is combined with Pravastatin.Investigational
RifabutinThe metabolism of Pravastatin can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Pravastatin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pravastatin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Pravastatin.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Pravastatin.Approved
RisperidoneThe serum concentration of Pravastatin can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Pravastatin can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of Pravastatin can be increased when it is combined with Rivastigmine.Approved, Investigational
RokitamycinThe risk or severity of rhabdomyolysis can be increased when Rokitamycin is combined with Pravastatin.Experimental
RolapitantThe serum concentration of Pravastatin can be increased when it is combined with Rolapitant.Approved, Investigational
RolitetracyclineThe serum concentration of Pravastatin can be increased when it is combined with Rolitetracycline.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Pravastatin.Approved
RoxithromycinThe serum concentration of Pravastatin can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Pravastatin can be increased when it is combined with Rucaparib.Approved, Investigational
RutinThe serum concentration of Pravastatin can be increased when it is combined with Rutin.Experimental, Investigational
SagopiloneThe risk or severity of rhabdomyolysis can be increased when Sagopilone is combined with Pravastatin.Investigational
SalbutamolThe serum concentration of Pravastatin can be increased when it is combined with Salbutamol.Approved, Vet Approved
SaquinavirThe serum concentration of Pravastatin can be decreased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Pravastatin can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Pravastatin can be increased when combined with Secobarbital.Approved, Vet Approved
SelamectinThe risk or severity of rhabdomyolysis can be increased when Selamectin is combined with Pravastatin.Vet Approved
SertralineThe serum concentration of Pravastatin can be increased when it is combined with Sertraline.Approved
SildenafilThe serum concentration of Pravastatin can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Pravastatin.Approved
SiltuximabThe serum concentration of Pravastatin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Pravastatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Pravastatin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Pravastatin can be increased when it is combined with Sirolimus.Approved, Investigational
SitaxentanThe serum concentration of Pravastatin can be increased when it is combined with Sitaxentan.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Pravastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SorafenibThe serum concentration of Pravastatin can be increased when it is combined with Sorafenib.Approved, Investigational
SpiramycinThe risk or severity of rhabdomyolysis can be increased when Spiramycin is combined with Pravastatin.Approved
St. John's WortThe metabolism of Pravastatin can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Pravastatin can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Pravastatin can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe serum concentration of Pravastatin can be increased when it is combined with Sulfamethoxazole.Approved
SulfanilamideThe serum concentration of Pravastatin can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe serum concentration of Pravastatin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Pravastatin can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Pravastatin can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilThe serum concentration of Pravastatin can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe serum concentration of Pravastatin can be increased when it is combined with Tamoxifen.Approved
TelaprevirThe serum concentration of Pravastatin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Pravastatin can be increased when it is combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Pravastatin can be increased when it is combined with Temsirolimus.Approved
TeniposideThe serum concentration of Pravastatin can be increased when it is combined with Teniposide.Approved
TerfenadineThe serum concentration of Pravastatin can be increased when it is combined with Terfenadine.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Pravastatin.Experimental
TeriflunomideThe serum concentration of Pravastatin can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Pravastatin can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Pravastatin can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Pravastatin can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Pravastatin can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Pravastatin can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Pravastatin can be increased when it is combined with Tetracycline.Approved, Vet Approved
ThiopentalThe serum concentration of Pravastatin can be increased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pravastatin.Approved, Withdrawn
TicagrelorThe serum concentration of Pravastatin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Pravastatin can be increased when it is combined with Ticlopidine.Approved
TildipirosinThe risk or severity of rhabdomyolysis can be increased when Tildipirosin is combined with Pravastatin.Vet Approved
TilmicosinThe risk or severity of rhabdomyolysis can be increased when Tilmicosin is combined with Pravastatin.Investigational, Vet Approved
TioconazoleThe serum concentration of Pravastatin can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Pravastatin can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Pravastatin can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe serum concentration of Pravastatin can be increased when it is combined with Tofisopam.Approved
TolbutamideThe metabolism of Pravastatin can be decreased when combined with Tolbutamide.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Pravastatin.Approved
TopiroxostatThe serum concentration of Pravastatin can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Pravastatin.Approved, Investigational
TrabectedinPravastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TramadolThe serum concentration of Pravastatin can be increased when it is combined with Tramadol.Approved, Investigational
TranylcypromineThe serum concentration of Pravastatin can be increased when it is combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe risk or severity of rhabdomyolysis can be increased when Trastuzumab emtansine is combined with Pravastatin.Approved, Investigational
TrimethoprimThe metabolism of Pravastatin can be decreased when combined with Trimethoprim.Approved, Vet Approved
TroglitazoneThe serum concentration of Pravastatin can be increased when it is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe serum concentration of Pravastatin can be increased when it is combined with Troleandomycin.Approved
TromethamineThe serum concentration of Pravastatin can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of rhabdomyolysis can be increased when Tylosin is combined with Pravastatin.Vet Approved
TylvalosinThe risk or severity of rhabdomyolysis can be increased when Tylvalosin is combined with Pravastatin.Vet Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Pravastatin.Approved, Investigational, Nutraceutical
Valproic AcidThe serum concentration of Pravastatin can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Pravastatin can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Pravastatin can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Pravastatin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Pravastatin can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Pravastatin can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Pravastatin can be increased when it is combined with Vincristine.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Pravastatin.Approved, Investigational
VinorelbineThe serum concentration of Pravastatin can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Pravastatin can be increased when it is combined with Voriconazole.Approved, Investigational
ZafirlukastThe serum concentration of Pravastatin can be increased when it is combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe serum concentration of Pravastatin can be increased when it is combined with Ziprasidone.Approved
ZucapsaicinThe serum concentration of Pravastatin can be increased when it is combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Take without regard to meals.

References

Synthesis Reference

Kae Jong Chung, Joo Kyung Lee, Joo Woong Park, Dong Jin Seo, Sang Choon Lee, "Method for producing pravastatin precursor, ML-236B." U.S. Patent US6204032, issued October, 1976.

US6204032
General References
Not Available
External Links
Human Metabolome Database
HMDB0005022
KEGG Drug
D08410
KEGG Compound
C01844
PubChem Compound
54687
PubChem Substance
46504851
ChemSpider
49398
BindingDB
20688
ChEBI
63618
ChEMBL
CHEMBL1144
Therapeutic Targets Database
DAP000550
PharmGKB
PA451089
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pravastatin
ATC Codes
C10AA03 — PravastatinC10BX02 — Pravastatin and acetylsalicylic acidC10BA03 — Pravastatin and fenofibrate
AHFS Codes
  • 24:06.08 — Hmg-coa Reductase Inhibitors
FDA label
Download (145 KB)
MSDS
Download (44 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedPreventionVentilator-associated Bacterial Pneumonia1
1Active Not RecruitingPreventionGlomerulonephritis minimal lesion / Hyperlipidemias1
1CompletedNot AvailableHealthy Volunteers4
1CompletedBasic ScienceCancer, Breast1
1CompletedBasic ScienceDrug Biotransformation / Membrane Transport1
1CompletedBasic ScienceDrug Interactions1
1CompletedBasic ScienceGenotype-related Drug Metabolism1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceRheumatoid Arthritis1
1CompletedOtherHealthy Volunteers / Rheumatoid Arthritis1
1CompletedTreatmentAcute Kidney Injury (AKI)1
1CompletedTreatmentDrug Distribution1
1CompletedTreatmentHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
1CompletedTreatmentLeukemias1
1CompletedTreatmentTherapeutic Equivalency2
1RecruitingNot AvailableHealthy Volunteers1
1RecruitingPreventionPreeclampsia1
1RecruitingTreatmentDyslipidemias / Peripheral Artery Disease (PAD)1
1RecruitingTreatmentLeukemias1
1, 2TerminatedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1, 2TerminatedTreatmentAlbinism, Oculocutaneous / Hermansky-Pudlak Syndrome (HPS) / Metabolic Diseases / Platelet Storage Pool Deficiency / Pulmonary Fibrosis1
2Active Not RecruitingTreatmentCHILD B / Hepatocellular,Carcinoma1
2Active Not RecruitingTreatmentLeukemias1
2CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
2CompletedTreatmentDiabetes Mellitus (DM) / High Blood Cholesterol Level / Metabolic Syndromes1
2CompletedTreatmentDyslipidemias1
2CompletedTreatmentHigh Blood Cholesterol Level / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHigh Blood Cholesterol Level / Statin-Associated Myopathy1
2CompletedTreatmentHutchinson-Gilford Syndrome / Progeria1
2CompletedTreatmentHypercholesterolemia, Familial1
2CompletedTreatmentLupus / Systemic Lupus Erythematosus (SLE)1
2Enrolling by InvitationTreatmentProgeria1
2Not Yet RecruitingTreatmentCoronary Heart Disease (CHD) / Human Immunodeficiency Virus (HIV) Infections1
2Not Yet RecruitingTreatmentTuberculosis1
2RecruitingTreatmentFibrosis1
2Unknown StatusTreatmentAdvanced Hepatocarcinoma1
2WithdrawnTreatmentInfection, Human Immunodeficiency Virus I1
2WithdrawnTreatmentMucocutaneous Lymph Node Syndrome1
3CompletedBasic ScienceHigh Blood Cholesterol Level / Hyperlipoproteinemias1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Myocardial Infarction (MI) / Myocardial Ischemia1
3CompletedPreventionCardiovascular Disease (CVD) / Kidney Diseases / Microalbuminuria1
3CompletedPreventionStroke, Ischemic1
3CompletedTreatmentArterial Occlusive Diseases / Cardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Heart Diseases / Vascular Diseases1
3CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD)1
3CompletedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3CompletedTreatmentChild-Pugh A Hepatocellular Carcinoma1
3CompletedTreatmentChronic Allograft Nephropathy (CAN) / End-Stage Renal Disease (ESRD)1
3CompletedTreatmentCombined Hyperlipidemia1
3CompletedTreatmentHigh Blood Cholesterol Level2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
3CompletedTreatmentHypercholesterolemia or Combined Dyslipidemia1
3CompletedTreatmentHyperlipidemias1
3CompletedTreatmentHyperlipoproteinemia Type III1
3CompletedTreatmentLiver Cancer1
3CompletedTreatmentLung Cancers1
3CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
3TerminatedTreatmentHigh Blood Cholesterol Level1
3TerminatedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedPreventionActue Coronary Syndromes1
4CompletedPreventionAging / Alzheimer's Disease (AD)1
4CompletedPreventionCardiovascular Disease (CVD)1
4CompletedPreventionHyperlipidemias1
4CompletedPreventionTraumatic Brain Injury (TBI)1
4CompletedTreatmentAcute Coronary Syndromes (ACS)1
4CompletedTreatmentCardiovascular Disease (CVD) / Glucose Metabolism / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Metabolic Abnormality / Metabolism, Lipids1
4CompletedTreatmentChronic Heart Failure (CHF)1
4CompletedTreatmentChronic Stable Angina Pectoris / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina Pectoris1
4CompletedTreatmentCoronary Arteriosclerosis1
4CompletedTreatmentCoronary Heart Disease (CHD) / High Blood Cholesterol Level1
4CompletedTreatmentDyslipidemias2
4CompletedTreatmentHigh Blood Cholesterol Level2
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hyperlipidemias2
4CompletedTreatmentHypertriglycemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentMulti-vessel Diseases, Angina1
4CompletedTreatmentMixed hypercholesterolemia / Primary Dyslipidemia1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
4CompletedTreatmentType IIa and IIb Hypercholesterolaemia1
4RecruitingHealth Services ResearchDiabetes Mellitus (DM)1
4RecruitingPreventionHigh Blood Pressure (Hypertension) / Strokes / Transient Ischaemic Attack (TIA)1
4RecruitingTreatmentChronic Kidney Disease (CKD)1
4RecruitingTreatmentCoronary Artery Disease1
4RecruitingTreatmentDiabetes Mellitus (DM) / Prediabetic State1
4TerminatedNot AvailableStatin Adverse Reaction / Statin-Associated Myopathy1
4TerminatedTreatmentChronic Kidney Disease (CKD)1
4TerminatedTreatmentHeart Failure, Unspecified1
4Unknown StatusPreventionAcute Myocardial Infarction (AMI)1
4Unknown StatusTreatmentCoronary Heart Disease (CHD) / High Blood Cholesterol Level1
4Unknown StatusTreatmentDrug-eluting Stent (DES)1
4Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections / Hyperlipidemias1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHigh Blood Cholesterol Level3
Not AvailableCompletedNot AvailablePediatrics Patients on Dialysis1
Not AvailableCompletedNot AvailablePostpartum Depression1
Not AvailableCompletedPreventionCardiovascular Disease Risk / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Refractory Anemia With Excess Blasts / Untreated Adult Acute Myeloid Leukemia1
Not AvailableCompletedTreatmentCoronary Artery Disease1
Not AvailableNot Yet RecruitingTreatmentEndometriosis1
Not AvailableRecruitingTreatmentCoronary Artery Occlusive Disease1
Not AvailableTerminatedPreventionHigh Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
Not AvailableTerminatedTreatmentMetabolic Syndromes1
Not AvailableUnknown StatusScreeningDyslipidemias1
Not AvailableUnknown StatusTreatmentCrohn's Disease (CD)1
Not AvailableUnknown StatusTreatmentHeart Diseases1
Not AvailableWithdrawnTreatmentEndometriosis1

Pharmacoeconomics

Manufacturers
  • Bristol myers squibb
  • Apotex corp
  • Dr reddys laboratories inc
  • Glenmark generics ltd
  • Lek pharmaceuticals dd
  • Lupin pharmaceuticals inc
  • Matrix laboratories ltd
  • Mylan pharmaceuticals inc
  • Pliva hrvatska doo
  • Ranbaxy laboratories ltd
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cadila Healthcare Ltd.
  • Cardinal Health
  • Cobalt Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • Dept Health Central Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • E.R. Squibb and Sons LLC
  • Glenmark Generics Ltd.
  • International Laboratories Inc.
  • Kaiser Foundation Hospital
  • Lek Pharmaceuticals Inc.
  • Lupin Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral10 mg
Kit; tablet; tablet, delayed releaseOral
TabletOral80 mg
TabletOral20 mg
TabletOral40 mg
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Prices
Unit descriptionCostUnit
Pravachol 40 mg tablet6.53USD tablet
Pravachol 80 mg tablet6.53USD tablet
Pravastatin sodium 40 mg tablet4.89USD tablet
Pravastatin sodium 80 mg tablet4.89USD tablet
Pravachol 20 mg tablet4.39USD tablet
Pravachol 10 mg tablet4.38USD tablet
Pravastatin sodium 20 mg tablet3.33USD tablet
Pravastatin sodium 10 mg tablet3.28USD tablet
Apo-Pravastatin 40 mg Tablet1.42USD tablet
Co Pravastatin 40 mg Tablet1.42USD tablet
Jamp-Pravastatin 40 mg Tablet1.42USD tablet
Mint-Pravastatin 40 mg Tablet1.42USD tablet
Mylan-Pravastatin 40 mg Tablet1.42USD tablet
Novo-Pravastatin 40 mg Tablet1.42USD tablet
Pms-Pravastatin 40 mg Tablet1.42USD tablet
Pravachol 40 mg Tablet1.42USD tablet
Ran-Pravastatin 40 mg Tablet1.42USD tablet
Ratio-Pravastatin 40 mg Tablet1.42USD tablet
Sandoz Pravastatin 40 mg Tablet1.42USD tablet
Apo-Pravastatin 20 mg Tablet1.18USD tablet
Co Pravastatin 20 mg Tablet1.18USD tablet
Jamp-Pravastatin 20 mg Tablet1.18USD tablet
Mint-Pravastatin 20 mg Tablet1.18USD tablet
Mylan-Pravastatin 20 mg Tablet1.18USD tablet
Novo-Pravastatin 20 mg Tablet1.18USD tablet
Pms-Pravastatin 20 mg Tablet1.18USD tablet
Pravachol 20 mg Tablet1.18USD tablet
Ran-Pravastatin 20 mg Tablet1.18USD tablet
Ratio-Pravastatin 20 mg Tablet1.18USD tablet
Sandoz Pravastatin 20 mg Tablet1.18USD tablet
Apo-Pravastatin 10 mg Tablet1.0USD tablet
Co Pravastatin 10 mg Tablet1.0USD tablet
Jamp-Pravastatin 10 mg Tablet1.0USD tablet
Mint-Pravastatin 10 mg Tablet1.0USD tablet
Mylan-Pravastatin 10 mg Tablet1.0USD tablet
Novo-Pravastatin 10 mg Tablet1.0USD tablet
Pms-Pravastatin 10 mg Tablet1.0USD tablet
Pravachol 10 mg Tablet1.0USD tablet
Ran-Pravastatin 10 mg Tablet1.0USD tablet
Ratio-Pravastatin 10 mg Tablet1.0USD tablet
Sandoz Pravastatin 10 mg Tablet1.0USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5622985No1994-10-222014-10-22Us
CA1323836No1993-11-022010-11-02Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)171.2 - 173°CMSDS
water solubilitySoluble FDA label
logP0.59 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.242 mg/mLALOGPS
logP2.23ALOGPS
logP1.65ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.21ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.29 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity113.6 m3·mol-1ChemAxon
Polarizability46.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uk9-0009000000-967b377abafe64b73071
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0002900000-bd7fd66d793ae64426ff
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-4809000000-0ed5a8797dfc49ecf5af
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-2900000000-91b125182ce5d90f16ab
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1900000000-e8fc6384260de93c5aa8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1900000000-11e99968bc0ba393b6f9
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-4900000000-0e4265e6dc1468c1471d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0002900000-8795ee00dded0ef8be48
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-3709000000-aa45be15af0471c0a46e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-2900000000-5617409991f5c58e5130
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-2900000000-2bf5c13979a639625d1c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-2900000000-9a233e521607e82ab7a0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0900000000-2083dfbb67bf2b03ccf9
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uk9-0009000000-4b2c09a295ba7f3ce41b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0607900000-e57e263ad3f74bfda195

Taxonomy

Description
This compound belongs to the class of organic compounds known as medium-chain hydroxy acids and derivatives. These are hydroxy acids with a 6 to 12 carbon atoms long side chain.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Medium-chain hydroxy acids and derivatives
Direct Parent
Medium-chain hydroxy acids and derivatives
Alternative Parents
Fatty alcohols / Medium-chain fatty acids / Hydroxy fatty acids / Fatty acid esters / Branched fatty acids / Beta hydroxy acids and derivatives / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / Carboxylic acids
show 3 more
Substituents
Fatty alcohol / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Branched fatty acid / Hydroxy fatty acid / Fatty acid ester / Fatty acyl / Dicarboxylic acid or derivatives / Secondary alcohol
show 10 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
statin (semi-synthetic), carboxylic ester, secondary alcohol, 3-hydroxy carboxylic acid, hydroxy monocarboxylic acid, carbobicyclic compound (CHEBI:63618)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
  2. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
  3. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
  4. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799]
  5. Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ: Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129-38. doi: 10.1097/FPC.0b013e32831bd98c. [PubMed:19151602]
  2. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351]
  3. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
  2. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  2. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
  2. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
  3. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150]
  2. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y: Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997 Oct;25(10):1123-9. [PubMed:9321514]
  3. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y: Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002 Feb 22;277(8):6497-503. Epub 2001 Dec 17. [PubMed:11748225]
  4. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043]
  2. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Symporter activity
Specific Function
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
Gene Name
SLC16A1
Uniprot ID
P53985
Uniprot Name
Monocarboxylate transporter 1
Molecular Weight
53943.685 Da
References
  1. Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A: Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res. 1995 Nov;12(11):1727-32. [PubMed:8592677]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Morisawa Y, Takikawa H: Effect of bile acids on the biliary excretion of pravastatin in rats. Hepatol Res. 2009 Jun;39(6):595-600. doi: 10.1111/j.1872-034X.2009.00493.x. Epub 2009 Feb 24. [PubMed:19260999]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Link [Link]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 22:57